Logo image of TLPH

TALPHERA INC (TLPH) Stock Fundamental Analysis

NASDAQ:TLPH - Nasdaq - US00444T2096 - Common Stock - Currency: USD

0.51  +0.02 (+4.59%)

After market: 0.4935 -0.02 (-3.24%)

Fundamental Rating

2

Taking everything into account, TLPH scores 2 out of 10 in our fundamental rating. TLPH was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of TLPH is average, but there are quite some concerns on its profitability. TLPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TLPH has reported negative net income.
TLPH had a negative operating cash flow in the past year.
TLPH had negative earnings in 4 of the past 5 years.
In the past 5 years TLPH always reported negative operating cash flow.
TLPH Yearly Net Income VS EBIT VS OCF VS FCFTLPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

The Return On Assets of TLPH (-77.65%) is worse than 71.28% of its industry peers.
Looking at the Return On Equity, with a value of -207.95%, TLPH is doing worse than 68.72% of the companies in the same industry.
Industry RankSector Rank
ROA -77.65%
ROE -207.95%
ROIC N/A
ROA(3y)-24.13%
ROA(5y)-35.67%
ROE(3y)-32.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLPH Yearly ROA, ROE, ROICTLPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TLPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLPH Yearly Profit, Operating, Gross MarginsTLPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

6

2. Health

2.1 Basic Checks

TLPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLPH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TLPH has been increased compared to 5 years ago.
There is no outstanding debt for TLPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TLPH Yearly Shares OutstandingTLPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TLPH Yearly Total Debt VS Total AssetsTLPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TLPH has an Altman-Z score of -45.02. This is a bad value and indicates that TLPH is not financially healthy and even has some risk of bankruptcy.
TLPH's Altman-Z score of -45.02 is on the low side compared to the rest of the industry. TLPH is outperformed by 90.26% of its industry peers.
There is no outstanding debt for TLPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -45.02
ROIC/WACCN/A
WACC9.53%
TLPH Yearly LT Debt VS Equity VS FCFTLPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 3.11 indicates that TLPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.11, TLPH is in line with its industry, outperforming 53.85% of the companies in the same industry.
A Quick Ratio of 3.11 indicates that TLPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.11, TLPH is in line with its industry, outperforming 58.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 3.11
TLPH Yearly Current Assets VS Current LiabilitesTLPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

TLPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.44%, which is quite impressive.
Looking at the last year, TLPH shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)49.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TLPH will show a very strong growth in Earnings Per Share. The EPS will grow by 30.67% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.33%
EPS Next 2Y-5.2%
EPS Next 3Y14.22%
EPS Next 5Y30.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLPH Yearly Revenue VS EstimatesTLPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
TLPH Yearly EPS VS EstimatesTLPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLPH. In the last year negative earnings were reported.
Also next year TLPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLPH Price Earnings VS Forward Price EarningsTLPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLPH Per share dataTLPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as TLPH's earnings are expected to grow with 14.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.2%
EPS Next 3Y14.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TALPHERA INC

NASDAQ:TLPH (6/6/2025, 8:00:01 PM)

After market: 0.4935 -0.02 (-3.24%)

0.51

+0.02 (+4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12
Inst Owners29.21%
Inst Owner ChangeN/A
Ins Owners1.24%
Ins Owner Change41.4%
Market Cap10.46M
Analysts82.22
Price Target4.25 (733.33%)
Short Float %1.14%
Short Ratio4.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.87%
Min EPS beat(2)34.64%
Max EPS beat(2)57.11%
EPS beat(4)4
Avg EPS beat(4)41.41%
Min EPS beat(4)34.64%
Max EPS beat(4)57.11%
EPS beat(8)7
Avg EPS beat(8)33.59%
EPS beat(12)10
Avg EPS beat(12)22.36%
EPS beat(16)13
Avg EPS beat(16)17.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)20%
EPS NQ rev (3m)50%
EPS NY rev (1m)6.85%
EPS NY rev (3m)36.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 387.22
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS0.27
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.65%
ROE -207.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.13%
ROA(5y)-35.67%
ROE(3y)-32.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 3.11
Altman-Z -45.02
F-Score1
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y9.33%
EPS Next 2Y-5.2%
EPS Next 3Y14.22%
EPS Next 5Y30.67%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.17%
OCF growth 3YN/A
OCF growth 5YN/A